News | August 01, 2023
Concord Biotech’s IPO to open on 4th August, 2023
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
CARA is a data and content management platform that helps companies in regulated industries such as finance, energy, and manufacturing transform their complex business processes
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
There is a pressing need for continuous improvement and innovation in food safety systems to keep pace with emerging food trends and habits
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
Advances clinical research capabilities with leading regulatory grade registries platform
Subscribe To Our Newsletter & Stay Updated
